Biopharmaceutical Research on the Choice of a Non-Steroidal Anti-Inflammatory Agent in the Development of Combination Gel for Mastopathy Therapy

The study aimed to justify the selection of non-steroidal anti-inflammatory drugs (NSAIDs) and their concentration for developing a combination gel for mastopathy treatment and breast cancer prevention. Using literary analysis, marketing research, and biopharmaceutical methods in vitro, the researchers identified indometacin as the active pharmaceutical ingredient (API) for the gel. The study established the concentration of indometacin in the gel based on biopharmaceutical studies. This research was significant in addressing the high incidence of breast cancer, particularly in Ukraine, where it was projected to affect nearly 17% of women by the end of 2020.